C
1.07
-0.02 (-1.83%)
| Previous Close | 1.09 |
| Open | 1.11 |
| Volume | 146,753 |
| Avg. Volume (3M) | 487,290 |
| Market Cap | 90,733,704 |
| Price / Book | 2.37 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.380 |
| Total Debt/Equity (MRQ) | 10.66% |
| Current Ratio (MRQ) | 0.360 |
| Levered Free Cash Flow (TTM) | -1.26 M |
| Return on Assets (TTM) | -22.41% |
| Return on Equity (TTM) | -93.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Citius Oncology, Inc. | Mixed | Bullish |
AIStockmoo Score
1.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 86.80% |
| % Held by Institutions | 0.60% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Dec 2025 | Announcement | Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update |
| 23 Dec 2025 | Announcement | Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update |
| 09 Dec 2025 | Announcement | Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules |
| 04 Dec 2025 | Announcement | Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim |
| 01 Dec 2025 | Announcement | Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) |
| 25 Nov 2025 | Announcement | Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |